VIDEO: Study data show efficacy of Miebo in range of patients with dry eye disease
Click Here to Manage Email Alerts
In this Healio Video Perspective from the World Ophthalmology Congress, John D. Sheppard, MD, MMSc, FACS, of Virginia Eye Consultants discusses Miebo’s efficacy for dry eye disease in various patient subgroups.
Data were collected from the phase 3 GOBI and MOJAVE registration trials, which investigated Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) as a treatment for signs and symptoms of dry eye disease.
“We are excited to report that not only did both trials show approvable data for signs and symptoms without need for additional study analysis, but also that these particular outcomes were agnostic to age, sex and initiation inclusion criteria,” Sheppard said.
Collapse
Law G, et al. Perfluorohexyloctane ophthalmic solution for dry eye disease is effective across a wide range of participant subgroups. Presented at: World Ophthalmology Congress; Aug. 16-19, 2024; Vancouver, British Columbia.
Read more about
Click Here to Manage Email Alerts